Quick Answer
Protagonist Therapeutics, Inc reported Total Assets of $668.19 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed a decrease of -10.3% in Total Assets from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $102.84 million | Q1 2017: $82.67 million | Q2 2017: $70.48 million | Q3 2017: $110.42 million | Q1 2018: $149.24 million | Q2 2018: $137.47 million | Q3 2018: $148.86 million | Q1 2019: $132.25 million | Q2 2019: $148.11 million | Q3 2019: $154.63 million | Q1 2020: $134.90 million | Q2 2020: $224.98 million | Q3 2020: $217.32 million | Q1 2021: $298.07 million | Q2 2021: $404.23 million | Q3 2021: $373.18 million | Q1 2022: $348.30 million | Q2 2022: $310.51 million | Q3 2022: $282.17 million | Q1 2023: $239.86 million | Q2 2023: $320.47 million | Q3 2023: $330.02 million | Q1 2024: $629.28 million | Q2 2024: $614.63 million | Q3 2024: $603.86 million | Q1 2025: $742.13 million | Q2 2025: $718.01 million | Q3 2025: $701.69 million.
- Over the full 11 years of available data (2015 to 2025), Protagonist Therapeutics, Inc's Total Assets has grown by 4,401.1%.
- Historical annual values: Fiscal year 2025: $668.19 million | Fiscal year 2024: $744.73 million | Fiscal year 2023: $357.95 million | Fiscal year 2022: $247.93 million | Fiscal year 2021: $347.70 million | Fiscal year 2020: $324.47 million | Fiscal year 2019: $154.92 million | Fiscal year 2018: $139.47 million | Fiscal year 2017: $163.73 million | Fiscal year 2016: $93.99 million | Fiscal year 2015: $14.85 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: